Formed in 2013, the Endocrine Neoplasia program is a joint effort between Duke Cancer Institute and the Duke Clinical Research Institute.
Focusing on cancers of the endocrine system, which includes the thyroid, parathyroid, pancreas and adrenal glands, our rapidly growing group of skilled clinicians and researchers offers a transdisciplinary approach to research and patient care.
Our program is committed to providing high-quality research and training. Our group is comprised of surgeons, endocrinologists, radiation oncologist, residents, fellows, health services researchers, epidemiologists, psychologists, and biostatisticians. The multidisciplinary nature of our program makes it ideal to tackle the pressing issues of endocrine neoplasms and work toward bridging gaps in patient care at the individual and population levels.
Although our primary focus is health services research and health outcomes, we are also interested in examining different issues along the continuum of patient care, including translational research, clinical trials for novel therapies and patient reported outcomes, among others.
Our research encompasses the different diseases of the thyroid, parathyroid, pancreas, and adrenal glands.
Translational Research: The endocrine neoplasia group has an encompassing interest in cross-disciplinary translational research, including parathyroid diseases (Koh Laboratory), and thyroid cancer (Counter Laboratory; Stapleton Laboratory)
Cancer Genetics: The endocrine neoplasia group has been working using genomic data of thyroid cancer, to develop a genetic signature that predicts progression. (Cheng Laboratory)
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.